Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants

Fidele Ntie-Kang1,2,*
Conrad Veranso Simoben1,2,*
Berin Karaman1
Valery Fuh Ngwa3
Philip Neville Judson4
Wolfgang Sipl1
Luc Meva’a Mbaze5

1Department of Pharmaceutical Chemistry, Martin-Luther University of Halle-Wittenberg, Halle (Saale), Germany; 2Department of Chemistry, University of Buea, Buea, Cameroon; 3Interuniversity Institute For Biostatistics and Statistical Bioinformatics (I-BioStat), University of Hasselt, Hasselt, Belgium; 4Chemical Bioactivity Information Centre, Harrogate, UK; 5Department of Chemistry, Faculty of Science, University of Douala, Douala, Cameroon

*These authors contributed equally to this work

Abstract: Molecular modeling has been employed in the search for lead compounds of chemotherapy to fight cancer. In this study, pharmacophore models have been generated and validated for use in virtual screening protocols for eight known anticancer drug targets, including tyrosine kinase, protein kinase Bβ, cyclin-dependent kinase, protein farnesyltransferase, human protein kinase, glycogen synthase kinase, and indoleamine 2,3-dioxygenase 1. Pharmacophore models were validated through receiver operating characteristic and Güner–Henry scoring methods, indicating that several of the models generated could be useful for the identification of potential anticancer agents from natural product databases. The validated pharmacophore models were used as three-dimensional search queries for virtual screening of the newly developed AfroCancer database (~400 compounds from African medicinal plants), along with the Naturally Occurring Plant-based Anticancer Compound-Activity-Target dataset (comprising ~1,500 published naturally occurring plant-based compounds from around the world). Additionally, an in silico assessment of toxicity of the two datasets was carried out by the use of 88 toxicity end points predicted by the Lhasa’s expert knowledge-based system (Derek), showing that only an insignificant proportion of the promising anticancer agents would be likely showing high toxicity profiles. A diversity study of the two datasets, carried out using the analysis of principal components from the most important physicochemical properties often used to access drug-likeness of compound datasets, showed that the two datasets do not occupy the same chemical space.

Keywords: anticancer, natural products, medicinal plants, pharmacophore, toxicity, virtual screening

Introduction

In spite of the enormous efforts and progress in the field of cancer research, cancer is the second most common disease-related cause of human mortality, only next to myocardial infarction. According to the recent World Health Organization reports, cancer alone is responsible for ~7.6 million deaths (~13% of all deaths) annually, and it is estimated that the threat of cancer-related diseases will worsen if no measures are taken. Additionally, plant-derived NPs have played a significant role in drug discovery, by being an important source of several clinically useful drugs, including anticancer agents.

A cancerous growth is often defined as any malignant tumor. A neoplasm or tumor is an abnormal mass of tissue whose growth exceeds that of normal tissues and whose growth is uncoordinated with that of the latter. Such cancerous growth continues in the same manner after cessation of the stimuli that had initiated it. The methods of cancer treatment include radiation therapy, surgery, and chemotherapy. However, the
first two treatment methods are only successful at the early localized stages of the disease, while chemotherapy is the main treatment method for malignancies because it has the ability to cure widespread cancer even at the later stages. In the search for lead compounds of cancer chemotherapy and prevention, research groups have often resorted to medicinal plants, based on their ethnomedical uses in the treatment of several cancer-related symptoms and ailments.9,11–25 This is because local and traditional knowledge has been the starting point for many successful drug development projects over the last few decades, as recorded in several literature references.9,10,16–18,26–28 The African flora, for example, is known to contain promising anticancer agents, both based on traditional knowledge and isolated bioactive metabolites that have tested positive against a number of cancer cell lines.29–31 In silico methods of drug discovery programs have proven to be useful in quickly providing lead compounds from enormous databases and also help in lead optimization. This justifies the development of compound libraries, particularly “focused” library scaffolds of compounds that have shown some potency in experimental assays against a particular disease or a drug target. A recent study showed that ~400 compounds from the African medicinal plants, with demonstrated in vitro and/or in vivo anticancer, cytotoxic, and antiproliferative activities, have been identified.32 This dataset (AfroCancer) has been compared with a larger dataset of ~1,500 compounds contained in the Naturally Occurring Plant-based Anticancer Compound-Activity-Target (NPACT) database and with the much larger dataset contained within the Dictionary of Natural Products.32–34 The drug-likeness properties of these plant-derived anticancer datasets have been explored in the previous studies, proving to be interesting starting points for anticancer lead discovery.72,23 It is noteworthy that approximately half of known anticancer drugs are either NPs or NP-related synthetic compounds.35–37 Despite the enormous potential of NPs from the African flora,38–40 little has been done to exploit them into real marketable drugs.41 This calls for efforts from within the continent for laying the groundwork for anticancer drug discovery projects from the floral matter.

The application of in silico (computer-based) modeling in the search for lead compounds is a promising endeavor in drug discovery, since it often accelerates the process and cuts down costs.42 Virtual screening methods are useful because, in principle, they narrow down the number of compounds to be actually tested in biological assays. This is practicable when the in silico scoring methods are sufficiently able to discriminate between active and inactive ones.43,44 The approaches of docking,45–47 quantitative structure-activity relationship,48,49 and pharmacophore searching47,49–51 have been previously employed with relative success in anticancer lead generation programs. The previous in silico modeling efforts targeting NPs from the African flora have been focused on the building of datasets for virtual screening30,54–56 and pharmacokinetic profiling of the derived datasets.50,57–59 The aim of the current study was to employ molecular modeling methods to access the toxicity profiles of the aforementioned datasets32,33 of promising plant-derived anticancer agents and to evaluate the performance of derived pharmacophore models for virtual screening, in a quest to identify new and/or promising anticancer lead compounds from the African flora.

Materials and methods
Data collection and analysis
The dataset for naturally occurring compounds with promising anticancer properties (AfroCancer) has been recently described.32 The compounds of the NPACT database were downloaded from the official webpage (http://crdd.osdd.net/ragava/npact/)34 and prepared for virtual screening as previously described.31

Pharmacophore modeling approach
All pharmacophore modeling was carried out using the LigandScout software (Inte:Ligand, Vienna, Austria).50 All protein–ligand complexes in this study were retrieved from the protein database61 and prepared as previously described.32 The datasets of active compounds against each drug target were identified from the literature sources cited in the Results section (Table 1). Small molecule modeling of the compounds active against each target was carried out using the Molecular Operating Environment (MOE) (Montreal, QC, Canada) software running on a Linux workstation with a 3.5 GHz Intel Core 2 Duo processor (San Jose, CA, USA). The three-dimensional (3D) structures were generated using the builder module of MOE, and energy minimization was subsequently carried out using the MMFF94 force field until a gradient of 0.01 kcal/mol was reached. In generating the 3D structures, both R and S forms of stereoisomers were generated in the case of racemic mixtures. Additionally, the ligand databases were given a preliminary treatment using the LigPrep software (Schrödinger LLC, NY, USA).64 Protonation states at biologically relevant pH were correctly assigned (group 1 metals in simple salts were disconnected, strong acids were deprotonated, strong bases were protonated, and explicit hydrogens were added), and conformers were generated. The generated conformer
datasets were further inspected visually, eg, piperazines were mono- or diprotonated taking into account the neighboring groups; piperidines, pyrrolidines, and tertiary aliphatic amines were charged positively always; pyrimidones were also represented as hydroxy pyrimidines; and for ethylenediamines, both neutral and monoprotonated forms were generated. The 3D structures of the compounds and conformers were then saved as individual .mol2 files, subsequently included into a MOE database (.mdb) file and exported to the .ldb file, which is suitable for use in virtual screening workflows using the LigandScout software.\(^{60}\) The performance of a pharmacophore model in virtual screening experiments is often tested by its ability to discriminate between known active compounds and decoys (supposed to be inactive). Such enrichment tests were performed on the set of active compounds (training set) and later used to screen for hits from the AfroCancer and NPACT libraries, using the generated pharmacophore models. In order to avoid artificial enrichment in assessing the performances of the generated pharmacophore models in virtual screening.

Both libraries of active compounds and decoys were run through or “fitted into” the generated pharmacophore models. The poses were scored (ranked) using the pharmacophore fit score function implemented in LigandScout.\(^{60}\) In general, true positive (TP)/false positive (FP) hit rates, true negative (TN)/false negative (FN) hit rates, enrichment factor (EF), goodness of hits, and the receiver operating characteristic (ROC) curve–area under the ROC curve (AUC) are among the most common quality parameters used in the pharmacophore model evaluation experiments. To assess the performance of each pharmacophore scoring scheme used in this study, some important measures were considered, eg, the percentage yield of active compounds \(Y_a\), percentage actives, and Goodness of a Hit list (Güner–Henry [GH] scoring). The percentage yield of actives was defined as the ratio of actives found in the hit list to the total number of compounds in the hit list, given by the following equation:

\[
Y_a = \frac{\text{TPs}}{\text{TPs} + \text{FPs}} \times 100
\]

where the TPs are defined as bioactive compounds that are correctly recognized by the pharmacophore model and the FPs are defined as inactive compounds that fit into the pharmacophore model. The percentage of actives represent the ratio of active compounds in the hit list (TPs) to the total

Table 1 Description of selected human anticancer drug targets used to generate the structure-based pharmacophores in this study

| PDB code | Drug target class or role | Resolution of X-ray crystal structure | Bioactive ligands | References |
|----------|--------------------------|-------------------------------------|------------------|------------|
| 1IEP     | Tyrosine kinase          | 2.10 Å                              | Pyrido[2,3-d]pyrimidine derivatives (eg, PD173955, PD173956, PD180970, and imatinib) and phenylamino-pyrimidines | 73–76 |
| 2DO      | PKB \(\beta\)            | 1.80 Å                              | 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides, 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines, and 6-phenylpurine | 77–79 |
| 2XMY     | CDK responsible for regulating transcription | 1.90 Å                              | 2-Anilino-4-(thiazol-5-yl)pyrimidines | 80 |
| 3E37     | Protein farnesyltransferase | 1.80 Å                              | Ethylenediamines | 81 |
| 3PE1     | Human protein kinase      | 1.60 Å and 1.90 Å, respectively     | 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines, ethylenediamines, 4-(thiazol-5-yl)benzoic acid derivatives, substituted N-phenylthieno[3,2-c]quinolin-4-aminnes, and pyrimido[4,5-c]quinoline-8-carboxylic acids | 82–85 |
| 4ACM     | Glycogen synthase kinase  | 1.63 Å                              | Sulfonamide pyrazines | 86, 87 |
| 4BBG     | Cell cycle regulator, critical for the assembly of the mitotic spindle | 2.50 Å                              | S-Trityl-L-cysteine-based inhibitors | 88 |
| 4PK5     | Indoleamine 2,3-dioxigenase I | 2.79 Å                              | Imidazothiazole derivatives | 89 |

Abbreviations: PDB, Protein Data Bank; PKB, Protein kinase B; CDK, cyclin-dependent kinase.
number of actives in the dataset (training set), given by the following equation:

\[
\text{\% yield} = \frac{\text{TPs}}{A} \times 100
\]  

(2)

where \(A\) is the total number of compounds in the dataset of actives. The sensitivity \((S_e)\), specificity \((S_p)\), and EF parameters shown in Equations 3–5, respectively, were computed and used as indicators of the GH score (Equation 6).66–68 ie, goodness of hit (GH score):

\[
S_e = \frac{\text{TPs}}{\text{TPs} + \text{FNs}}
\]

(3)

\[
S_p = \frac{\text{TNs}}{\text{TNs} + \text{FPs}}
\]

(4)

\[
\text{EF} = \frac{Y_s}{A/D}
\]

(5)

\[
\text{GH} = \left(\frac{3}{4}Y_s + \frac{1}{4}S_e\right)S_p
\]

(6)

where FNs are bioactive compounds that are not recognized by a model, TNs are inactive compounds that do not fit into the pharmacophore model, and \(D\) is the total number of compounds in each dataset (actives + decoys). The GH score ranges from 0 to 1, where a value of 1 signifies an ideal model and a value of 0 signifies a null model. The ROC curve is a graphical plot of the TP rate \((S_e)\) versus FP rate \((1-S_p)\), while the AUC is an important method of measuring the performance of the test. The equation for computing the AUC is shown as follows:

\[
\text{AUC} = \sum_{x=2}^{N} S_e(x)[(1-S_p(x)) - (1-S_p(x-1))]
\]

(7)

where \(S_e(x)\) is the percent of the TP at position \(x\) and \((1-S_p(x))\) is the percent of the FP versus the total negatives at rank position \(x\).

**In silico toxicity assessment methods**

Toxicity prediction was carried out using Lhasa’s expert knowledge-based predictive tool, Derek software Version 3.0.1 (Lhasa Ltd, Leeds, UK),69 running on Nexus 1.5.0 platform. The two datasets (AfroCancer and NPACT) were input in .sdf format. The chosen species was human beings, and 88 toxicity end points were predicted. A full list of the predicted end points has been provided in the Supplementary materials. The toxicity prediction run was carried out for both AfroCancer and NPACT datasets, and the results were analyzed.

**Diversity analysis of the AfroCancer and NPACT datasets**

Diversity analysis was done by the principal component analysis (PCA) method [68] implemented in the MOE package.52 A number of simple descriptor parameters for the two datasets (AfroCancer and NPACT) were generated using the molecular descriptor calculator included in the QuSAR module of the MOE package.62 The computed descriptors include the MW, number of rotatable single bonds, lipophilicity (log \(P\)), solubility (log \(S\)), number of HBAs, number of HBDs, total hydrophobic surface area, total polar surface area, number of oxygen, number of chiral centers, number of rings, and number of Lipinski violations. In order to select the optimum number of molecular descriptors for the molecules of both datasets, QuSAR-Contingency (a statistical application in MOE) was employed. The dimensionality of the best selected descriptors, obtained from QuSAR-Contingency, was further reduced by linear transformation of the data by PCA.70 This resulted in a new (smaller) table of descriptors that are uncorrelated and normalized (mean \(=0\) and variance \(=1\)). All computed descriptors were employed in the PCA, while the minimum variance was set at 98% for the final set of principal components retained. The 3D plots of the best three principal components (PCA1, PCA2, and PCA3) for both datasets were plotted on the same set of coordinate axes, with PCA1 on the \(x\)-axis, PCA2 on the \(y\)-axis, and PCA3 on the \(z\)-axis, each point on a dataset in the coordinate axes representing a molecule. In order to analyze the diversity of the scaffolds in both datasets, the compounds were fragmented using the retrosynthetic combinatorial analysis procedure algorithm.71 The LibMCS program of JKlustor was used for maximum common substructure clustering of the two datasets.72 The frequency of occurrence of each scaffold in the two datasets was computed and ranked. The most common substructures (most common substructure selection [MCSS]) of the two datasets were then tabulated and compared.

**Overall rationale of the modeling methods**

Data related to the protein–ligand complexes73–89 used to generate pharmacophore models for virtual screening are listed in Table 1. The biological significance of the drug targets for which the pharmacophore models were generated has been discussed in our previous study.12 Pharmacophore-based virtual screening is often an efficient method for the identification of potentially new lead compounds for further
development from a virtual database. Molecules that satisfy the features of the pharmacophore models used as the 3D query are retained as hits. In this study, 3D pharmacophore models were generated and validated, while the best pharmacophore models were used as a 3D search query for retrieving potent molecules from the AfroCancer and NPACT chemical databases, which could be proposed for bioassays. The performance of each pharmacophore model was evaluated using ROC analysis, based on their ability to selectively capture diverse active compounds against the chosen targets from a large list of decoys or inactives. The numbers of conformers of actives and decoys for each target and characteristics for GH or “goodness of hit” scoring (eg, $S_p$, $S_v$, EF, $Y_p$, and % yield of actives) are listed in Table 2.

In this study, the GH method was used to assess the pharmacophore models generated. This is because this method has been previously used to quantify model selectivity (best model), accuracy of hits, and the recall of actives from a molecule dataset consisting of known actives and inactives with relative success. The GH score has been applied for quantifying model selectivity and covering the activity space from database mining successfully and for evaluating the effectiveness of similarity search in databases containing both structural and biological activity data. GH scoring contains a coefficient used to penalize excessive hit list size when evaluating hit lists. This coefficient is calibrated by weighting the score with respect to the yield and coverage. The GH scores were computed following Equation 7, and

Table 2 Summary of performances of pharmacophore models in virtual screening study

| PDB code | Actives | Decays | Hit rate | Total hits | TP | FP | TN |
|----------|---------|--------|----------|------------|----|----|----|
| 1IEP     | 45      | 2,250  | 0.52     | 12         | 9  | 3  | 2,247 |
| 2JDO     | 19      | 950    | 16.41    | 159        | 4  | 155 | 795  |
| 2XMY     | 14      | 700    | 4.20     | 30         | 7  | 23 | 677  |
| 3E37a    | 10      | 500    | 40.78    | 208        | 6  | 202 | 298  |
| 3E37b    | 10      | 500    | 44.71    | 228        | 5  | 223 | 277  |
| 3E37c    | 10      | 500    | 10.98    | 56         | 2  | 54 | 446  |
| 3PE1i    | 274     | 15,250 | 4.31     | 669        | 206 | 463 | 14,780 |
| 3PE1ii   | 274     | 15,250 | 0.30     | 47         | 41 | 6  | 15,237 |
| 3PE2     | 274     | 15,250 | 6.19     | 960        | 11 | 949 | 14,294 |
| 4ACM     | 42      | 2,150  | 3.51     | 77         | 23 | 54 | 2,096 |
| 4BBGc    | 76      | 3,800  | 3.12     | 121        | 48 | 73 | 3,726 |
| 4BBGd    | 76      | 3,800  | 2.40     | 93         | 45 | 48 | 3,751 |
| 4BBGe    | 76      | 3,800  | 4.02     | 156        | 63 | 93 | 3,706 |
| 4PKSi    | 29      | 1,450  | 5.34     | 79         | 6  | 73 | 1,377 |
| 4PKSj    | 29      | 1,450  | 5.47     | 81         | 6  | 75 | 1,375 |

FN $Y_p$ % yield $S_p$ $S_v$ EF GH

| 1IEP     | 36      | 75.00  | 20       | 0.20       | 0.99 | 3.825 | 0.75a |
| 2JDO     | 15      | 2.51   | 21       | 0.21       | 0.84 | 128  | 0.32  |
| 2XMY     | 7       | 23.33  | 50       | 0.50       | 0.97 | 1,190 | 0.58a |
| 3E37a    | 4       | 2.88   | 60       | 0.60       | 0.60 | 147  | 0.93a |
| 3E37b    | 5       | 2.19   | 50       | 0.50       | 0.55 | 112  | 0.79a |
| 3E37c    | 8       | 3.57   | 20       | 0.20       | 0.89 | 182  | 0.29  |
| 3PE1i    | 68      | 30.79  | 75       | 0.75       | 0.97 | 1,744| 0.71a |
| 3PE1ii   | 233     | 87.23  | 15       | 0.15       | 0.99 | 4,940| 0.26  |
| 3PE2     | 263     | 1.15   | 4        | 0.04       | 0.94 | 65   | 0.54a |
| 4ACM     | 19      | 29.87  | 55       | 0.55       | 0.97 | 1,559| 0.57a |
| 4BBGc    | 28      | 39.67  | 63       | 0.63       | 0.98 | 2,023| 0.57a |
| 4BBGd    | 31      | 48.39  | 59       | 0.39       | 0.99 | 2,467| 0.46  |
| 4BBGe    | 13      | 40.38  | 83       | 0.83       | 0.98 | 2,059| 0.75a |
| 4PKSi    | 23      | 7.59   | 21       | 0.21       | 0.95 | 387  | 0.29  |
| 4PKSj    | 23      | 7.41   | 21       | 0.21       | 0.95 | 378  | 0.29  |

Notes: 3E37-i model is a four-point pharmacophore centered on two HBA and two hydrophobic centers; 3E37-ii model is a three-point pharmacophore centered on two HBAs and one hydrophobic center; 3E37-iii model is a three-point pharmacophore centered on one HBD and two HBA and two hydrophobic centers; 3PKS-ii model is a three-point pharmacophore centered on one HBD, one HBA, and two hydrophobic centers; 4PKS-j model is a four-point pharmacophore centered on one positive ionizable group; 4BBG-II model is a four-point pharmacophore similar to the 4BBG-I model, except that an hBD replaces the positive ionizable group in the former model; 4BBG-III model is almost identical to 4BBG-I, but separated by exclusion volumes; 4PKS-ii model is a three-point pharmacophore centered on one HBD and two hydrophobic centers; and 4PKS-ii model is an almost identical model to 4PKS-I, but separated by exclusion volumes. GH score: >0.50.

Abbreviations: PDB, Protein Data Bank; TP, true positive; FP, false positive; TN, true negative; FN, false negative; EF, enrichment factor; GH, Güner–Henry; HBA, H-bond acceptor; HBD, H-bond donor.
the values are listed in Table 2, ranging from 0 to 1, with 0 indicating a null model and 1 a perfect model (containing only actives and no decoys).\(^6\) For a good model, the GH value is expected to be $>0.7$.\(^7\) The most promising models have been marked with an asterisk (*) on the respective GH score value. Finally, the ROC curve is a function of $S_e$ versus the $S_p$, and the AUC value is an important method of measuring the performance of the test.

**Results and discussion**

**Assessment of pharmacophore models generated**

For the 1IEP target, for example, the best derived pharmacophore model was composed of a combination of an HBA (Acc) feature located on the carbonyl of the native ligand separated from an HBD (Don1) and two hydrophobic centers (Hyd1 and Hyd2), respectively, by 4.97 Å, 4.14 Å, and 3.64 Å (Figure 1). The second HBD feature (Don2) was located between the two hydrophobic centers, with respective distances of 2.90 Å and 3.80 Å from Hyd1 and Hyd2 (Figure 1). Scoring of this pharmacophore model using the pharmacophore fit score implemented in LigandScout\(^58\) resulted in the identification of nine out of the 45 generated active conformers in the hit list composed of only 12 hits (hit rate = 0.52; Table 2). Even though the hit rate is weak, the $Y_a$, % yield, $S_e$, $S_p$, EF, and GH scores are, respectively, 75%, 20%, 0.20, 0.99, 3,825, and 0.75 (Table 2).

Two separate high-performance pharmacophore models were generated for the 3PE1 target (I and II; Figure 2) with the common features comprising the HBD (Don), the acceptor (Acc2), and the hydrophobic center (Hyd2; Figure 2A and B). Even though the pharmacophore model 3PE1-I was composed of many more features (as shown in Figure 2A, C and D) than the 3PE1-II (Figure 2B and E), the first model gave a much higher yield, selectivity, and GH score. Meanwhile, the second model performed better in terms of $Y_a$ values because it scored up to 41 out of the 47 compounds in the hit list, even though a total of up to 274 compounds were present in the original list of actives. The performance of this human protein kinase pharmacophore model was also tested for the Protein Data Bank code 3PE2 (with only three features, one corresponding to the common acceptor in models 3PE1-I and 3PE1-II; Figure 3). The specificity of this pharmacophore model was comparable with that of the earlier models (3PE1-I and 3PE1-II), while the GH score was midway between that of the 3PE1 models. The performances of these pharmacophores reveal that the

![Figure 1](image1.png)

**Figure 1** A pharmacophore model used to screen for potential active compounds against the 1IEP target.

**Notes:** (A) Projected within the target site (B) with highlighted pharmacophore features located on atomic centers of the native ligand, with HBDs and HBAs in blue and hydrophobic centers in yellow. (C) Interactions between native ligand and target site amino acid residues, with hydrophobic interactions shown in light brown, HBD interactions with the native ligand in green, and acceptor interactions in red. (D) Locations of centers of pharmacophore features on the native ligand showing distances between the centers, with distance measurements shown in red. This model led to the identification of only nine out of the 45 generated active conformers in the hit list composed of only 12 hits (hit rate = 0.52).

**Abbreviations:** HBDs, H-bond donors; HBAs, H-bond acceptors.
3PE1-I model could be suitable for initially screening a huge dataset, while the more specific model (3PE1-II) could be more suitable in cases of small datasets, which might be the results from a hit list derived from a primary screen of a large dataset using the 3PE1-I model query. The third model (3PE2) is rather less selective, “picking up” too many FPs, thus resulting in a very low $S_e$ value (0.04) and rendering this model the least desirable of the three pharmacophores that could be used in screening for human protein kinase inhibitors in this study.

Figure 2 Two sets of combinations of high-performance pharmacophore models for the 3PE1 target.

Notes: For (A and B), the highlighted pharmacophore features are located on the atomic centers of the native ligand, with HBDs and HAs in blue and hydrophobic centers in yellow, for the two pharmacophore models (3PE-I and 3PE-II, with carbon atoms portrayed in cyan and gray, respectively). (C) Interactions between native ligand and target site amino acid residues, with hydrophobic interactions shown in light brown, HBD interactions with the native ligand in green, and acceptor interactions in red. For (D and E), representing 3PE-I and 3PE-II, respectively, the locations of centers of pharmacophore features on the native ligand show distances between the centers, with distance measurements shown in red. These are the best overall performing pharmacophore models in this study.

Abbreviations: HBDs, H-bond donors; HAs, H-bond acceptors.
The validated model for the 4ACM target has been shown in Figure 4, while the remaining models are given in Figures S1–S5. The 4ACM model is composed of two HBAs centered, respectively, on the sulfonyl and pyrazine ring; one HBD on the amino substituent of the pyrazine ring; and a hydrophobic center on the benzene ring. The interactions between the native ligand used to generate this model and the target binding site residues are shown in Figure 4, while the distances between feature centers are shown in Figure 4D. This model was able to capture up to 23 out of the 42 compounds (50% yield of actives), with the strength of the model being the fact that the $S'_e$, $S'_p$, and GH scores were all $\geq 0.50$. Meanwhile, the 3E37-I model (Figure S3-I) was able to capture six out of the ten active compounds in the original dataset of actives as the top scoring hits. Our study also involved pharmacophore models for the protein kinase B (PKB) $\beta$, Protein Data Bank code 2JDO, which has been recently explored by Vyas et al in a virtual screening study, giving a much weaker model than reported in the previous study.

The ROC curves used to evaluate the performances of the generated pharmacophore models are shown in Figures 5 and 6 for three of the “best” models. Figure 5 shows the enrichment curve for the 3PE1-I model. The TP rate has also been plotted against the FP rate and used to compare the two 4BBG models (I and III) for the purpose of comparison (Figure 6). Both 4BBG models show better enrichment than the 3PE1-I model, with the 4BBG-III model (Figure 6B) having a higher AUC value than the 4BBG-I model (Figure 6A).
Pharmacophore-based virtual screening of AfroCancer and NPACT datasets

The best derived pharmacophore hypotheses were employed as 3D search queries against the AfroCancer and NPACT datasets. Compounds that had their chemical groups spatially overlapping (mapping) with the corresponding features, ie, molecules that satisfied all the features of the pharmacophore model used as the 3D query of the particular pharmacophoric model, were captured as hits and ranked following their pharmacophore fitness score, as implemented in LigandScout. A summary of the virtual screening results (number of hits and hit rates) for the AfroCancer and NPACT datasets, using the established and validated pharmacophore models, is given in Table 3. It was generally observed that, apart from the null case (model 4BBG-II), the hit rates for the virtual screening of the much smaller AfroCancer dataset were higher than those for the NPACT. Moreover, a plot of the ranks of the retrieved hits by pharmacophore fit scores against the number of compounds screened in the respective databases showed a better performance for the AfroCancer, eg, for the 4ACM pharmacophore model; this curve is shown in Figure 7.

Assessment of the toxicological profiles of the AfroCancer and NPACT datasets

Assessment of the toxicological profiles of the AfroCancer and NPACT datasets was run on the Derek Nexus platform. Derek Nexus is an expert, knowledge-based software that gives informative toxicity predictions quickly. The ability to predict potential toxicity of either the parent compound

Figure 4 A pharmacophore model used to screen for potential active compounds against the 4ACM target.

Notes: (A) Projected within the target site (B) with highlighted pharmacophore features located on atomic centers of the native ligand, with HBDs and HBAs in blue and hydrophobic centers in yellow. (C) Interactions between native ligand and target site amino acid residues, with hydrophobic interactions shown in light brown, HBD interactions with the native ligand in green, and acceptor interactions in red. (D) Locations of centers of pharmacophore features on the native ligand showing distances between the centers, with distance measurements shown in red. This model was able to capture up to 23 out of the 42 compounds (% yield of actives =55%) in the original database of actives, with a hit rate of 3.51% from the total database of actives and decoys. Meanwhile, the S_f, S_p, and GH values for this model were all ±0.55.

Abbreviations: HBDs, H-bond donors; HBAs, H-bond acceptors; GH, Güner–Henry.

Figure 5 The ROC curve for the 3PE1-1 pharmacophore model.

Note: The ROC curve is shown in blue, while the random line is shown in red.

Abbreviation: ROC, receiver operating characteristic.

Figure 6 The ROC curve for the 3Pe1-i pharmacophore model.
or its metabolites is important in the novel drug design programs.\textsuperscript{99,100} Computer-based assessment of potential toxicity has become increasingly popular in the past decade.\textsuperscript{99–102} Thus, early and accurate in silico toxicity prediction using Derek Nexus is an acceptable way of identifying potentially toxic chemicals, by helping experts to reject unsuitable drug candidates.\textsuperscript{99} The Derek system is able to perceive chemical substructures within molecules and relate these to a rule base, linking the substructures with likely types of toxicity.\textsuperscript{99–102} It is intended to aid the selection of compounds based on toxicological considerations or separately to indicate specific toxicological properties to be assayed early in the evaluation of a compound, thus saving time, cutting down costs, and saving the lives of some laboratory animals.\textsuperscript{103,104} This works through the identification of toxicity alerts within the chemical structures of a possible drug candidate. Alerts are collections of structural features observed to result in toxicological activity. Lhasa’s Nexus platform helps automate alert identification by mining descriptions of activating structural features or substructures directly from toxicity datasets, which have been included within the program’s knowledge base.\textsuperscript{105} Each rule contained in the rule base describes the

### Table 3 Comparison of virtual screening results (number of compounds in hit list and hit rates) for the AfroCancer and NPACT datasets of the pharmacophore models generated

| PDB code | AfroCancer |  | NPACT |  |
|----------|------------|------------------|------|------------------|
|          | Number of hits | Hit rate (%) | Number of hits | Hit rate (%) |
| 1ieP     | 12          | 3.07*           | 11   | 0.70             |
| 2JDO     | 107         | 27.37*          | 338  | 21.47            |
| 2XMY     | 69          | 17.65*          | 223  | 14.17            |
| 3E37    | 189         | 48.34           | 882  | 56.04            |
| 3E37    | 228         | 58.31*          | 907  | 57.62            |
| 3E37    | 95          | 24.30           | 440  | 27.95            |
| 3PE1    | 37          | 9.46            | 149  | 9.47             |
| 3PE1    | 3           | 0.77*           | 3    | 0.19             |
| 3PE2    | 106         | 27.11*          | 367  | 23.32            |
| 4ACM    | 35          | 8.95*           | 110  | 6.99             |
| 4BBG    | 26          | 6.65*           | 93   | 5.91             |
| 4BBG    | 0           | 0.00            | 0    | 0.00             |
| 4BBG    | 1           | 0.26*           | 3    | 0.19             |
| 4PK5    | 94          | 24.04*          | 301  | 19.12            |
| 4PK5    | 102         | 26.09*          | 308  | 19.57            |

**Notes:** *Hit rate for AfroCancer supersedes that of NPACT; 3E37-I model is a four-point pharmacophore centered on two HBAs and two hydrophobic centers; 3E37-II model is a three-point pharmacophore centered on two HBAs and one hydrophobic center; 3E37-III model is a three-point pharmacophore centered on two HBAs and one hydrophobic center; 3PE1-I model is a six-point pharmacophore centered on one HBD, three HBAs, and two hydrophobic centers; 3PE1-II model is a four-point pharmacophore centered on one HBD, one HBA, and two hydrophobic centers; 4BBG-I model is a four-point pharmacophore centered on one positive ionizable group; 4BBG-II model is a four-point pharmacophore similar to the 4BBG-I model, except that an HBD replaces the positive ionizable group in the former model; 4BBG-III model is almost identical to 4BBG-I, but separated by exclusion volumes; 4PK5-I model is a three-point pharmacophore centered on one HBD and two hydrophobic centers; and 4PK5-II model is an almost identical model to 4PK5-I, but separated by exclusion volumes.

**Abbreviations:** NPACT, Naturally Occurring Plant-based Anticancer Compound-Activity-Target; PDB, Protein Data Bank; HBA, H-bond acceptor; HBD, H-bond donor.
Potential anticancer agents from African medicinal plants

relationship between a structural feature or toxicophore and its associated toxic effect. Derek possesses the particular ability to report the reasoning behind its predictions. The rules are derived by an evaluation of toxicological, mechanistic, and physicochemical data. This is achieved by an argumentation-based approach using general toxicological and physicochemical concepts, eg, log \( P \). In this study, an attempt has been made to identify structural patterns within the AfroCancer and NPACT datasets, which may be related to toxicity of some of the compounds. Of the 390 compounds within the AfroCancer dataset, 1,330 tautomers were generated. A corresponding 5,357 tautomers were also generated for the NPACT dataset. Predictions were carried out for all the tautomers. In some cases, the output “NOTHING TO REPORT” was recorded. This means that these compounds do not contain any toxicophores that are described in Derek’s current knowledge base. The proportion of tautomers with the NOTHING TO REPORT output was 5.93% for AfroCancer and 4.39% for NPACT. This could also imply that the models in DEREK may not be in the applicability domain of the compounds with the NOTHING TO REPORT output. The remaining compounds showed a number of toxicophores identified with a wide range of toxicity end points. The Derek Nexus prediction includes an overall conclusion about the likelihood of toxicity in a structure and detailed reasoning information for the likelihood (or confidence level). The confidence levels are classified as CERTAIN, PROBABLE, PLAUSIBLE, EQUIVOCAL, and DOUBTED, based on experimental evidence and computed physicochemical parameters. It is important to mention that an outcome “CERTAIN” indicates that the query compounds themselves (or very closely related analogs) have been tested and found to be active. A definition of these confidence levels is provided in Table S1. As an example, chromosome damage in vitro was predicted to be CERTAIN for two compounds from the AfroCancer dataset (Figure 8). The log \( P \)-value of both compounds, imperatorin and bergapten (isolated from the stem of Balsamocitrus paniculata and the related Cameroonian rutaceae species), was computed to be 4.01, while the computed \( K_p \) was −1.52. The coumarin imperatorin is an antimutagen, also known to exert antihypertrophic effect both in vitro and in vivo, as well as antimicrobial activities. Both imperatorin and bergapten are also known to be components of the apiaceous Bishop’s weed (Ammi majus), growing wild in Egypt and the Mediterranean (a plant used for the treatment of leucoderma and skin diseases).

Figure 7 Enrichment curves obtained by screening the database compounds consisting of the AfroCancer database (blue) and NPACT database (green), using the 4ACM pharmacophore query features.
Notes: Selection and rank ordering of the compounds in the database were performed using the pharmacophore fit scoring function implemented in LigandScout. The AfroCancer performed better than the NPACT.
Abbreviation: NPACT, Naturally Occurring Plant-based Anticancer Compound-Activity-Target.

Figure 8 Psoralen substructure responsible for chromosome damage predicted as CERTAIN for two compounds from the AfroCancer dataset.
Notes: (A) Imperatorin and (B) bergapten, isolated from the stem of Balsamocitrus paniculata harvested in Cameroon and related plant species. The toxicity end point was predicted by Derek to be CERTAIN. Thus, these compounds may rather be toxic, not necessarily exhibiting anticancer activities.
The two coumarins activated the Derek alert for psoralen, which causes human chromosome damage in the in vitro chromosome aberration test.111 Experimental evidence suggests that activity in the in vitro chromosome aberration test may be a result of their DNA intercalating properties. The noncovalent binding of psoralen and several derivatives between two base pairs of DNA has been demonstrated.112 This mechanism is also supported by the weak mutagenic activity observed for several psoralen derivatives in the Ames test in Salmonella typhimurium strain TA1537,113 a strain that appears sensitive to other DNA intercalators.114,115

For the NPACT dataset, hepatotoxicity was predicted to be CERTAIN for one tautomer, ocular toxicity for two tautomers, and skin sensitization for six tautomers. The toxicophores responsible for these outcomes will be discussed separately. A total of 22 and 32 end points gave predictions, ranging from CERTAIN to DOUBTED for the AfroCancer and NPACT datasets, respectively (Table 4). “DOUBTED” means Derek predicts this compound to be INACTIVE but is not very confident about the conclusion, maybe because of absence of further experimental evidence. A bar chart showing the distribution of the percentage of compounds per likelihood for each end point has been represented in Figure 9 for both AfroCancer and NPACT datasets for chromosome damage in vitro, along with the totals. It was observed that the proportions of tautomers predicted with extreme likelihoods for the various toxicity end points (CERTAIN, PROBABLE, and DOUBTED) were relatively small when compared with the likelihoods PLAUSIBLE and EQUIVOCAL; eg, the bar charts in Figure 9A show that 8.5% and 9.4% of the generated tautomers were predicted as PLAUSIBLE for chromosome damage in vitro (an end point whose data are well distributed among the various aforementioned likelihoods) for the AfroCancer and NPACT datasets, respectively, when compared with equivalent percentages of 0.45% and 0.29% for the likelihoods CERTAIN, PROBABLE, and DOUBTED put together. Regarding the totals (Figure 9B), 93.6% of the generated tautomers were predicted as either PLAUSIBLE or EQUIVOCAL for all likelihoods of the AfroCancer dataset, with an equivalent 80.5% for the NPACT dataset. The Derek program uses the terms “CERTAIN”, “PROBABLE”, and “PLAUSIBLE” to express confidence in predictions based on criteria such that a record in the database reports the query itself to have been tested on the query species and found to be active, a record in the database reports the query itself to have been tested on a species related to the query species (but not on the species itself) and found to be active, and there are no relevant test results in the database but the query triggers at least one alert for activity and it is within the applicability domain for the model. The terms DOUBTED and IMPROBABLE are not weak predictions of activity – they mean that there are clear reasons to predict inactivity. Predictions of PLAUSIBLE or EQUIVOCAL may also imply that either experimental evidence is not strong enough to demonstrate that such toxicity is CERTAIN or that there are both arguments for and against such likelihood. Among the end points computed, the proportion of tautomers with predictions for skin sensitization was most pronounced, corresponding to 47.2% of all predictions for the AfroCancer dataset and 36.9% for the NPACT dataset. Our previous study had shown that the predicted maximum transdermal transport rates, \( J_m \) (in \( \mu \text{cm}^2 \text{h}^{-1} \)), computed from the aqueous solubility \( S_{\text{wat}} \) and skin permeability \( K_p \) and MW using the relation 8:

\[
J_m = K_p \times \text{MW} \times S_{\text{wat}} 
\]

indicated variations from 0 \( \mu \text{cm}^2 \text{h}^{-1} \) to 365 \( \mu \text{cm}^2 \text{h}^{-1} \), with only \(-1.6%\) of the compounds in AfroCancer having the predicted value of \( J_m > 100 \mu \text{cm}^2 \text{h}^{-1} \). However, 91.8% of the compounds were predicted to fall within the recommended range of the \( K_p \) parameter for >95% of known drugs. Skin sensitization studies may be relevant for molecules involved in drug discovery programs for skin cancers. Some of the end points may, however, be irrelevant for a study of anticancer agents. For example, potential eye irritation would not be of interest for an anticancer agent intended to be taken orally. A number of toxicophores responsible for the skin sensitization predictions will be discussed separately. Whether the compounds within both datasets of naturally occurring potential anticancer agents would be suitable starting points for lead discovery against skin cancers would be subject to further (experimental) investigations. hERG channel inhibition in vitro was predicted as PLAUSIBLE for <2% of compounds from the AfroCancer, with a corresponding only 2.46% of the compounds from the NPACT. This parameter had given a compliance of 58.5% and 62.6% for the recommended range of >95% of known drugs in our previous study.32

**Diversity of the AfroCancer and NPACT datasets**

In order to reduce redundancy and enhance the coverage of biological activity and chemical space, a dataset for virtual screening must have the requirement of diversity. PCA was used as a means of comparing the extent of diversity of the two datasets. This consists of reducing the dimensionality of the calculated descriptors by linearly transforming the data,
| Endpoints                                      | CERTAIN | PROBABLE | PLAUSIBLE | EQUIVOCAL | DOUBTED |
|-----------------------------------------------|---------|----------|-----------|-----------|---------|
|                                               | AfroCancer | NPACT | AfroCancer | NPACT | AfroCancer | NPACT | AfroCancer | NPACT | AfroCancer | NPACT |
| Carcinogenicity                               | –       | –       | –         | 1        | 17      | 107   | 71      | 134   | –         | –     |
| Cardiotoxicity                                | –       | –       | –         | –        | –       | –     | –       | –     | –         | –     |
| Cholinesterase inhibition                     | –       | –       | –         | –        | 1       | 1     | –       | –     | –         | –     |
| Chromosome damage in vitro                    | 2       | –       | 4         | 16       | 113     | 503   | 9      | 132   | –         | –     |
| Chromosome damage in vivo                     | –       | –       | –         | 6        | 6       | 11    | 1      | 18    | –         | –     |
| Cyanide-type effects                          | –       | –       | –         | –        | 1       | –     | –       | –     | –         | –     |
| Developmental toxicity                        | –       | –       | –         | –        | 15      | 76    | –       | –     | –         | –     |
| Genotoxicity in vitro                         | –       | –       | –         | –        | 17      | 72    | –       | –     | –         | –     |
| Hepatotoxicity                                | –       | 1       | –         | 2        | 58      | 173   | –       | –     | –         | –     |
| hERG channel inhibition in vitro              | –       | –       | –         | –        | 25      | 132   | –       | –     | –         | –     |
| Irritation (of the eye)                       | –       | –       | –         | –        | 17      | 133   | –       | –     | –         | –     |
| Irritation (of the gastrointestinal tract)    | –       | –       | –         | –        | 6       | 6     | –       | –     | –         | –     |
| Irritation (of the respiratory tract)         | –       | –       | –         | –        | 17      | 133   | –       | –     | –         | –     |
| Irritation (of the skin)                      | –       | –       | –         | –        | 17      | 133   | –       | –     | –         | –     |
| Mutagenicity in vitro                         | –       | –       | –         | 18       | 70      | –     | –       | –     | –         | –     |
| Neurotoxicity                                 | –       | –       | –         | 2        | –       | –     | –       | –     | –         | –     |
| Ocular toxicity                               | –       | 2       | –         | –        | –       | –     | –       | –     | –         | –     |
| Estrogenicity                                 | –       | –       | –         | 9        | –       | –     | –       | –     | –         | –     |
| Phospholipidosis                              | –       | –       | –         | 2        | –       | –     | –       | –     | –         | –     |
| Photoallergenicity                            | –       | –       | –         | 40       | 77      | –     | –       | –     | 2         | –     |
| Photocarcinogenicity                          | –       | –       | –         | 1        | 5       | 2     | –       | –     | –         | –     |
| Phototoxicity                                 | –       | –       | –         | –        | 1       | 12    | 28      | –     | –         | –     |
| Rapid prototypes: bladder disorders           | –       | –       | –         | –        | –       | –     | 1       | 4     | –         | –     |
| Rapid prototypes: cardiotoxicity              | –       | –       | –         | –        | –       | –     | –       | 1     | –         | –     |
| Rapid prototypes: chromosome damage in vitro  | –       | –       | –         | –        | –       | –     | –       | 9     | –         | –     |
| Rapid prototypes: hepatotoxicity              | –       | –       | –         | –        | –       | 5     | 18      | –     | 558       | –     |
| Rapid prototypes: mitochondrial dysfunction    | –       | –       | –         | –        | –       | 25    | 56      | –     | –         | –     |
| Rapid prototypes: nephrotoxicity              | –       | –       | –         | –        | –       | 131   | 546     | –     | –         | –     |
| Rapid prototypes: thyroid toxicity            | –       | –       | –         | –        | –       | –     | 6       | –     | –         | –     |
| Skin sensitization                           | –       | 6       | –         | 3        | 564     | 1,568 | 64      | 190   | –         | 208   |
| Teratogenicity                                | –       | –       | –         | 2        | 5       | 13    | –       | –     | –         | –     |
| Thyroid toxicity                              | –       | –       | –         | 8        | 52      | –     | –       | –     | –         | –     |
| **Total**                                     | 2       | 9       | 4         | 31       | 926     | 3,172 | 319     | 1,142 | 0         | 768   |

**Abbreviation:** NPACT, Naturally Occurring Plant-based Anticancer Compound-Activity-Target.
by calculating a new and smaller set of descriptors, which are uncorrelated and normalized. The PCA scatter plot of the previously calculated physicochemical properties of the AfroCancer (red) and NPACT dataset (blue), shown in Figure 10, is a visual representation of the molecules in the respective datasets, as described by the three best selected principal components (PCA1, PCA2, and PCA3). Each point shown corresponds to a molecule, with the spread of the points representing the diversity of the respective datasets. In this study, a comparison was carried out for the diversity of the two datasets, with the intention of examining the chemical spaces of the two datasets. From the 3D scatter plot of the three best principal components, obtained from the uncorrelated normalized descriptors (Figure 10), the regions close to the center of the cube contain some regions of intersection of chemical spaces of the two datasets. The larger number of outliers in the case of the NPACT dataset (away for the center and toward the left side of the cube) indicates a wider sampling of the chemical space, when compared with the AfroCancer collection. However, it stands out clear that the right side of the cube is dominated by components from the AfroCancer dataset, while the left side is dominated by components from the NPACT dataset. Overall, the NPACT occupies a wider region of chemical space than the AfroCancer. The first three PCAs could explain 89% (AfroCancer) and 87% (NPACT) of variance of the individual datasets. The MCSS panel for compound selection in the two datasets (Figure 11) is based on the substructures that can be synthetically combined and are common in “drug-like” molecules, allowing a direct selection and identification of compounds containing such substructures. The panel highlights the large diversity of the rings present in the NPs of both datasets, but a broad diversity is clearly seen in the MCSSs, apart from ethers, olefins, and carbonyl-bonded aromatic esters, featuring among the most common fragments obtained in the two datasets.

Conclusion

Based on this study, three main objectives have been attained: pharmacophore models for virtual screening aimed at the identification of naturally occurring anticancer agents have been generated and validated, the toxicity of the components of two datasets containing naturally occurring potential anticancer agents has been assessed in computer-based methods, and a diversity analysis of the two datasets has been carried out. This sets the stage for further identification and development of high affinity compounds with potential activities against eight known anticancer drug targets, including tyrosine kinases.
### A

| Name                                           | Frequency | Name                                           | Frequency | Name                                           | Frequency | Name                                           | Frequency | Name                                           | Frequency |
|------------------------------------------------|-----------|------------------------------------------------|-----------|------------------------------------------------|-----------|------------------------------------------------|-----------|------------------------------------------------|-----------|
| [OH₂:ether]                                    | 102       | [CH₂:ester]C                                   | 65        | [CH₂:olefin]C                                  | 53        | [O₁[CH₂:ether]C]                               | 18        |                                                               |           |
| [O₁[CH₂:ether]C]                               | 18        | [CH₄:ether]C                                   | 14        | [O₁CC(O)C(O)C(O)CH₂:et]                       | 13        | [O₁[CH₂:ether]C]                               | 12        |                                                               |           |
| c10ccc11(CH₃:olefin)                           | 11        | [O₁[CH₂:ether]C]                               | 10        | [O₁[CH₂:ester]CH₃:olefin]                     | 10        | [O₁[CH₂:ether]C]                               | 9         |                                                               |           |
| [O₁[CH₂:ether]C]                               | 9         | [CH₂:amide]C                                   | 9         | [O₁[CH₂:ester]C]                               | 9         | [O₁[CH₂:ether]C]                               | 8         |                                                               |           |

### B

| Name                                           | Frequency | Name                                           | Frequency | Name                                           | Frequency | Name                                           | Frequency | Name                                           | Frequency |
|------------------------------------------------|-----------|------------------------------------------------|-----------|------------------------------------------------|-----------|------------------------------------------------|-----------|------------------------------------------------|-----------|
| [OH₂:ether]                                    | 542       | [CH₂:olefin]C                                  | 266       | [CH₂:ester]C                                  | 216       | [CH₄:olefin]C                                  | 133       |                                                               |           |
| [CH₃:olefin]C                                  | 71        | [O₁[CH₂:ester]CH₃:olefin]                      | 67        | [O₁:CH₂:ether][C@@H]                          | 62        | [CH₄:ether]C                                   | 61        |                                                               |           |
| O10ccc11(CH₃:olefin)                           | 49        | [CH₄:ether]C                                   | 34        | [C(CH₂:olefin)C]                               | 30        | [O₁[CH₂:ether][C@@H]                          | 25        |                                                               |           |
| [O₁[CH₂:ester]c10ccc1]                         | 24        | [O₁[CH₂:ester]CH₂:olefin]                      | 22        | [c10ccc11(CH₃:olefin)]                        | 20        | [O₁CC(OC)c10(CH₃:olefin)]                      | 19        |                                                               |           |
| C(C(CH₃:olefin))[CH₂:ol1]                      | 16        | [O₁[CH₂:ether][C@H](O)                         | 15        | C(C(CH₃:olefin)]                               | 14        | [O₁C@H](O)[C@@H]                              | 13        |                                                               |           |

**Figure 11** MCSS panel in (A) AfroCancer and (B) NPACT, featuring the most common substructures included in the databases.

**Abbreviations:** MCSS, most common substructure selection; NPACT, Naturally Occurring Plant-based Anticancer Compound-Activity-Target.
kinase, PKB β, cyclin-dependent kinase, protein farnesyltransferase, human protein kinase, glycogen synthase kinase, and indoleamine 2,3-dioxygenase 1. The advantage of this work is that both datasets evaluated are relatively small and easy to screen virtually, even using a laptop personal computer. After virtual screening runs using the established pharmacophore-based models, a significant numbers of virtual “hits” have been identified from the datasets of both compounds. These could be further assayed using classical “wet lab” experiments. Moreover, predictions from Derek show that only a few of the compounds in both datasets could be potentially toxic to an extent that might make them unsuitable for investigation as potential cancer therapy. Diversity analysis using the three most important principal components of the computed physicochemical properties of the compounds in the two datasets shows that the databases do not occupy the same chemical space. The two datasets therefore represent reasonable starting virtual libraries for the identification of naturally occurring plant-based anticancer lead compounds for drug discovery.

Acknowledgments

Financial assistance is acknowledged from Lhasa Limited, Leeds, UK. Computational resources were made available through the Molecular Simulations Laboratory, Department of Chemistry, University of Buea, Cameroon. InteLigand Inc. is acknowledged for the academic license to use LigandScout. FN-K currently holds a Georg Forster fellowship from the Alexander von Humboldt Foundation, Germany, while CVS is currently a PhD student funded by the German Academic Exchange Services (DAAD).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science. 2000;287(5460):1969–1973.
2. WHO Media Centre [webpage on the Internet]. Fast sheet N° 297; 2013. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed February 4, 2014.
3. [webpage on the Internet]. Globocan Fast Stats; 2008. Available from: http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php. Accessed August 4, 2013.
4. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep. 2000;17(3):215–234.
5. Hostettmann K, Terreux C. Search for new lead compounds from higher plants. Chima. 2000;54(11):652–657.
6. Saklani A, Katty SK. Plant-derived compounds in clinical trials. Drug Discov Today. 2008;13(3):161–171.
7. Salim AA, Chin YW, Kinghorn AD. Drug discovery from plants. In: Ramawat KG, Merillon JM, editors. Bioactive Molecules and Medicinal Plants. Heidelberg: Springer; 2008:1–24.
8. Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. J Nat Prod. 2011;74(6):1539–1555.
9. Grothaus PG, Cragg GM, Newman DJ. Plant natural products in anti-cancer drug discovery. Curr Org Chem. 2010;14(16):1781–1791.
10. Ashutosh K. Medicinal Chemistry. New Delhi, India: New Age International Ltd.; 2007:794.
11. Desai AG, Quzi GN, Ganju RK, et al. Medicinal plants and cancer chemoprevention. Curr Drug Metab. 2008;9(7):581–591.
12. Heinrich M, Brenmer P. Ethnobotany and ethnopharmacy – their role for anti-cancer drug development. Curr Drug Targets. 2006;7(3):239–245.
13. Cragg GM, Newman DJ. Nature: a vital source of leads for anticancer drug development. Phytochem Rev. 2009;8(2):313–331.
14. Hollofy F, Kéri G. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. Curr Med Chem Anticancer Agents. 2004;4(2):173–197.
15. Clardy J, Walsh C. Lessons from natural molecules. Nature. 2004;432(7019):829–837.
16. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Ther. 2003;99(1):1–13.
17. Lucas DM, Still PC, Perez LB, Grever MR, Kinghorn AD. Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets. 2010;11(7):812–822.
18. Wang HK, Lee KH. Plant-derived anticancer agents and their analogs currently in clinical use or in clinical trials. Bot Bull Acad Sinica. 1997;38:225–235.
19. Pan L, Chai H, Kinghorn AD. The continuing search for antitumor agents from higher plants. Phytochem Lett. 2010;3(1):1–8.
20. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1):72–79.
21. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78(5):431–441.
22. Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanna SP. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem. 2005;13(21):5892–5908.
23. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009;109(7):3012–3043.
24. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med. 2006;27(1):1–93.
25. Nobili S, Lippi D, Witort E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res. 2009;59(6):365–378.
26. Lee KH. Anticancer drug design based on plant-derived natural products. J Biomed Sci. 1999;6(4):236–250.
27. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol. 2007;9(12):767–776.
28. Connors T. Anticancer drug development: the way forward. Oncologist. 1996;1(3):180–181.
29. Fadeyi SA, Fadeyi OO, Adejumo AA, Okoro C, Myles EL. In vitro anticancer screening of 24 locally used Nigerian medicinal plants. BMC Complement Altern Med. 2013;13(1):79.
30. Ntie-Kang F, Zofou D, Babiaka SB, et al. AfroDb: a select highly potent database. J Nat Prod. 2011;74(6):1539–1555.
31. Sawadogo WR, Schumacher M, Teiten MH, Dicato M, Diederich M. Traditional West African pharmacopeia, plants and derived compounds for cancer therapy. Biochem Pharmacol. 2012;84(10):1225–1240.
32. Ntie-Kang F, Nwodo JN, Ibezim A, et al. Molecular modeling of potential anticancer agents from African medicinal plants. J Chem Inf Model. 2014;54(9):2433–2450.
33. Ntie-Kang F, Lfongo LL, Judson PN, Sippel W, Efang SMN. How “drug-like” are naturally occurring anti-cancer compounds? J Mol Model. 2014;20(1):1–13.
34. Mangal M, Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013;41(D1):D1124–D1129.
35. Cragg GM, Newman DJ. Plants as a source of anti-cancer and anti-HIV agents. Ann Appl Biol. 2003;143(2):127–133.
36. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311–335.
37. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70(3):461–477.
38. Hostettmann K, Marston A, Ndjoko K, Wolfender JL. The potential of African plants as a source of drugs. Curr Org Chem. 2000;4(10): 973–1010.
39. Sandberg F, Perera-Ivarsson P, El-Seedi HR. A Swedish collection of medicinal plants from Cameroon. J Ethnopharmacol. 2005;102(3): 336–343.
40. El-Seedi HR, Burman R, Mansour A, et al. The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: discovery of an active cardiac glycoside from Urginea maritima. J Ethnopharmacol. 2013;145(3):746–757.
41. Efange SMN. Natural products: a continuing source of inspiration for the medicinal chemist. In: Iwu MM, Wootton JC, editors. Ethnomedicine and Drug Discovery; Advances in Phytomedicine. Vol. 1. Amsterdam, Netherlands: Elsevier Science; 2002:61–69.
42. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2): 151–185.
43. Klebe G. Virtual ligand screening strategies; perspective and limitations. Drug Discov Today. 2006;11(15):580–594.
44. Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel. 1998;1(1):4–15.
45. Chen H, Yao K, Nadas J, et al. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One. 2012;7(5):e38261.
46. Paul J, Gnanam R, Jayadeepa RM, Arul L. Anti cancer activity on Graviola, an exciting medicinal plant extract vs various cancer cell lines and a detailed computational study on its potent anti-cancerous leads. Curr Top Med Chem. 2013;13(14):1666–1763.
47. Vyas VK, Ghate M, Goel A. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein Kinase B (PKB β) inhibitors. J Mol Graph Model. 2013;42:17–25.
48. Fan Y, Shi LM, Kohn KW, Pommier Y, Weinstein JN. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. J Med Chem. 2001;44(20):3254–3263.
49. Zhou H, Wu S, Zhai S, et al. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinedione derivatives targeting drug-resistant lung cancer cells. J Med Chem. 2008;51(5):1242–1251.
50. Chiang YK, Kuo CC, Wu YS, et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem. 2009;52(14):4221–4233.
51. Kim DY, Kim KH, Kim ND, et al. Design and biological evaluation of novel tubulin inhibitors as antiinertic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006;49(19):5664–5670.
52. Ojima I, Chakravarty S, Inoue T, et al. A common pharmacophore for cytoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A. 1999;96(8):4256–4261.
53. Pérez-Sacau E, Díaz-Penãte RG, Estévez-Braun A, et al. Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line. J Med Chem. 2007;50(4):696–706.
54. Ntie-Kang F, Mbah JA, Mbaze LM, et al. CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med. 2013;13:88.
55. Ntie-Kang F, Onguéné P, Scharfe M, et al. ConMedNP: a natural medicinal chemist. In: Iwu MM, Wootton JC, editors. Ethnomedicine and Drug Discovery; Advances in Phytomedicine. Vol. 1. Amsterdam, Netherlands: Elsevier Science; 2002:61–69.
56. Ntie-Kang F, Onguéné PA, Scharfe M, et al. CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med. 2013;13:88.
57. Ntie-Kang F, Mbah JA, Lifongo LL, et al. Assessing the pharmacokinetic profile of the CamMedNP natural products database: in silico approach. Org Med Chem Lett. 2013;3(1):10.
58. Onguéné PA, Ntie-Kang F, Mbah JA, et al. The potential of anti-malarial compounds derived from African medicinal plants, part III: in silico evaluation of drug metabolism and pharmacokinetics profiling. Org Med Chem Lett. 2014;4(1):6.
59. Wolber G, Langer T, LigandScout: 3D-pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005;45(1):160–169.
60. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242.
61. Chemical Computing Group Inc. Molecular Operating Environment, Version 2010. Montreal: Chemical Computing Group Inc; 2010.
62. Chemical Computing Group Inc. Molecular Operating Environment, Version 2010. Montreal: Chemical Computing Group Inc; 2010.
63. Halgren TA. Merck molecular forcefield. J Comput Chem. 1996;17:490–441.
64. Schrödinger LLC. LigPrep Software, Version 2.5. New York: Schrödinger LLC; 2011.
65. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem. 2012;55(14):6582–6594.
66. Güner OF, Henry DR. Pharmacophore perception, development, and use in drug design. In: Güner OF, editor. Metric for Analyzing Hit Lists and Pharmacophores; IUL Biotechnology Series. La Jolla, CA: International University Line; 2000:191–212.
67. Güner OF, Waldman M, Hoffmann RD, Kim JH. Pharmacophore perception, development, and use in drug design. In: Güner OF, editor. Strategies for Database Mining and Pharmacophore Development; IUL Biotechnology Series, 1st Edition. La Jolla, CA: International University Line; 2000:213–236.
68. Langer T, Hoffmann RD. Pharmacophores and Pharmacophore Searches. Weinheim, Germany: WILEY-VCH; 2006:338–340.
69. Lhasa Limited [webpage on the Internet]. Derek Nexus. Available from: http://www.lhasalimited.org/products/derek-nexus.htm. Accessed May 19, 2015.
70. Wold S, Esbensen K, Geladi P. Principal component analysis. Chemometr Intell Lab Syst. 1987;2:37–52.
71. Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP – retroversitic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Med Chem Inf Comput Sci. 1998;38(3):511–522.
72. ChemAxon [webpage on the Internet]. JChem Software, Version 5.11.3. 2012. Available from: https://www.chemaxon.com/jchem/doc/user/LibMCS.html. Accessed May 19, 2015.
73. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62(15):4236–4243.
74. Wisniewski D, Lambeck CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-Kit receptor tyrosine kinases. Cancer Res. 2002;62(15):4244–4255.
75. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB. Potent and selective inhibitors of the Abb-kinase: phenylaminopyrimidines (Pap) derivatives. Bioorg Med Chem Lett. 1997;329(7):187–192.
76. Kräker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW. Biochemical and cellular effects of c-Src kinase-selective pyrrolido[2, 3-d]pyrimidines tyrosine kinase inhibitors. Biochem Pharmacol. 2000;60(7):885–898.
77. McHardy T, Caldwell JJ, Cheung KM, et al. Discovery of 4-amino-1- (7H-pyrrilo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J Med Chem. 2010;53(5):2239–2249.
78. Caldwell JJ, Davies TG, Donald A, et al. Identification of 4-((4-aminopyrimidin-1-yl)-7H-pyrrilo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem. 2008;51(7):2147–2157.
79. Donald A, McHardy T, Rowlands MG, et al. Rapid evolution of 6-phenylurea inhibitors of protein kinase B through structure-based design. J Med Chem. 2007;50(10):2289–2292.
80. Wang S, Griffiths G, Midgley CA, et al. Discovery and characterization of 2-amino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. *Chem Biol*. 2010;17(10):1111–1121.

81. Hast MA, Fletcher S, Cummings CG, et al. Structural basis for binding and selectivity of antimalarial and anticancer ethylendiamine inhibitors to protein famesyltransferase. *Chem Biol*. 2009;16(2):181–192.

82. Battistutta R, Cozza G, Pierre F, et al. Unprecedented selectivity and structural determinants of a new class of protein kinase c22 inhibitors in clinical trials for the treatment of cancer. *Biochemistry*. 2011; 50(39):8478–8488.

83. Pierre F, Stefan E, Nédélec AS, et al. 7-(4H-1,2,4-triazol-3-yl)benzof[1,2,6]napthyridines: a novel class of Pin kinase inhibitors with potent cell antiproliferative activity. *Bioorg Med Chem Lett*. 2011; 21(22):6687–6692.

84. Hou Z, Nakanishi I, Kinoshita T, et al. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds. *J Med Chem*. 2012;55(6):2899–2903.

85. Pierre F, Regan CF, Chevrel MC, et al. Novel potent dual inhibitors of CK2 and Pin kinases with antiproliferative activity against cancer cells. *Bioorg Med Chem Lett*. 2012;22(9):3327–3331.

86. Berg S, Bergh M, Hellberg S, et al. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer’s disease: design, synthesis, and characterization of pyrazines. *J Med Chem*. 2012;55(21):9107–9119.

87. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. *Chem Biol*. 2000;7(10):791–803.

88. Good JA, Wang F, Rath O, et al. Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. *J Med Chem*. 2013;56(5):1878–1893.

89. Tojo S, Kohno T, Tanaka T, et al. Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors. *ACS Med Chem Lett*. 2014;5(10):1119–1123.

90. Fawcett T. An introduction to ROC analysis. *Pattern Recognit Lett*. 2006;27(8):861–874.

91. Yang JM, Shen TW. A Pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators. *Proteins*. 2005; 59(2):205–220.

92. Muegge I. Selection criteria for drug-like compounds. *Med Res Rev*. 2003;23(3):302–321.

93. Ntie-Kang F, Kannan S, Wichapong K, Sippl W, Megnassan E. Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(P)SA analysis. *Mol Biosyst*. 2014;10(2):223–239.

94. Liao HS, Liu HL, Chen WH, Ho Y. Structure-based pharmacophore modeling and virtual screening, and molecular docking studies. *J Biomed Sci*. 2011;18:8.

95. Koide Y, Uemoto K, Hasegawa T, et al. Pharmacophore-based design of thalidomide-1-phosphate-3-receptor antagonists that include a 3,4-diaikoxycybenzophenone scaffold. *J Med Chem*. 2007;50(3):442–454.

96. Lu SH, Wu JW, Liu HL, et al. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. *J Biomed Sci*. 2011;18:8.

97. Seal A, Yogeswar P, Stram D, OSDD Consortium, Wild DJ. Enhanced ranking of PkaB inhibitors using data fusion methods. *J Cheminform*. 2013; 5(1):2.